JP3938632B2 - Oral composition - Google Patents

Oral composition Download PDF

Info

Publication number
JP3938632B2
JP3938632B2 JP14552698A JP14552698A JP3938632B2 JP 3938632 B2 JP3938632 B2 JP 3938632B2 JP 14552698 A JP14552698 A JP 14552698A JP 14552698 A JP14552698 A JP 14552698A JP 3938632 B2 JP3938632 B2 JP 3938632B2
Authority
JP
Japan
Prior art keywords
water
weight
fatty acid
medicinal component
insoluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP14552698A
Other languages
Japanese (ja)
Other versions
JPH11335253A (en
Inventor
裕久 上村
元 山崎
和彦 加藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP14552698A priority Critical patent/JP3938632B2/en
Publication of JPH11335253A publication Critical patent/JPH11335253A/en
Application granted granted Critical
Publication of JP3938632B2 publication Critical patent/JP3938632B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、非水溶性薬効成分の口腔粘膜、特に歯ぐきへの吸着率が向上した口腔用組成物に関する。
【0002】
【従来の技術】
口腔用組成物は通常薬効成分を含有し、その薬効剤が口腔内の患部に作用して口腔内の種々の疾患を予防、治療するものである。このような口腔用組成物において最も重要な機能は、配合された薬効成分が口腔内患部に吸着され、有効に作用することである。しかしビタミンE等の非水溶性薬効成分を配合する場合、界面活性剤を多量に必要とするため風味が悪く、またすすぎ時に薬効成分が排出してしまい、粘膜に吸着するものはほとんどなかった。
【0003】
これを解決するため、例えばN−α−ヤシ油脂肪酸アシル−L−アルギニンエチルエステルのDL−ピロリドンカルボン酸塩(CAE)を非水溶性薬効成分、エタノール、水とともに配合し、メジアン径を2μm以下としたエマルション状口腔用組成物(特開平4−5221号公報)が知られている。
【0004】
【発明が解決しようとする課題】
しかし、特開平4−5221号公報の口腔用組成物は、歯ぐきへの非水溶性薬効成分の吸着性についてはある程度優れているが、より優れた吸着性向上効果が求められており、またメジアン径が小さくなりすぎると粘膜への吸着性が低下するという問題もあった。さらにCAEを比較的多量に用いるため、風味の点で必ずしも満足できるものではなかった。
【0005】
したがって本発明は、口腔内粘膜、特に歯ぐきへの非水溶性薬効成分の吸着性がさらに向上し、風味にも優れた口腔用組成物を提供することを目的とする。
【0006】
【課題を解決するための手段】
本発明者らは、従来粒径が小さくなりすぎると粘膜への薬効成分の吸着性が低下すると考えられていたが、長鎖アシル塩基性アミノ酸アルキルエステルまたはその塩と非イオン性界面活性剤とを併用してメジアン径0.1μm以下のマイクロエマルションとすれば、口腔内粘膜、特に歯ぐきへの薬効成分の吸着性がさらに向上し、しかも長鎖アシル塩基性アミノ酸アルキルエステルまたはその塩の配合量を低減できるため風味も向上することを見出し、本発明を完成した。
【0007】
すなわち本発明は、非水溶性薬効成分0.001〜2重量%、N−α− 8 〜C 22 脂肪酸アシル−L−アルギニンアルキルエステルまたはその塩、非イオン性界面活性剤、水及びエタノールを含有し、非イオン性界面活性剤の含有量は非水溶性薬効成分に香料を加えた合計量に対して130〜250重量%、エタノールの含有量は非水溶性薬効成分に香料を加えた合計量に対して100〜250重量%であり、メジアン径0.1μm以下のマイクロエマルションからなる口腔用組成物を提供するものである。
【0008】
【発明の実施の形態】
本発明において非水溶性薬効成分は特に限定されず、例えば非水溶性ビタミン類(A、D、E、F、K、P等)及びその誘導体、グリチルレチン酸、アズレン誘導体、ステロイド類、抗プラスミン剤、非水溶性殺菌剤、フタライド類、ニコチン酸誘導体、並びにマロニエ、バーチ、センキュウ、トウキ、オトギリソウ、センブリ、ヒバマタ等の生薬の有機溶剤抽出物等が挙げられ、これらを1種以上用いることができる。非水溶性薬効成分の配合量は、0.001〜2重量%、特に0.01〜1重量%が好ましい。
【0009】
N−α−長鎖アシル塩基性アミノ酸アルキルエステルのアシル基は、炭素数8〜22の飽和または不飽和の天然または合成脂肪酸残基が好ましく、ヤシ油脂肪酸残基が特に好ましい。塩基性アミノ酸部分は、例えばオルニチン、リジン、アルギニンが好ましく、アルギニンが特に好ましい。塩基性アミノ酸部分は光学活性体でもラセミ体でもよい。アルキルエステルはメチルエステル、エチルエステル、プロピルエステル等の低級アルキルエステルが好ましく、エチルエステルが特に好ましい。
【0010】
N−α−長鎖アシル塩基性アミノ酸アルキルエステルの塩は、塩酸塩等の無機酸塩、ピロリドンカルボン酸塩等の有機酸塩が好ましく、ピロリドンカルボン酸塩が特に好ましい。N−α−長鎖アシル塩基性アミノ酸アルキルエステルまたはその塩として最も好ましいのは、CAEである。N−α−長鎖アシル塩基性アミノ酸アルキルエステルまたはその塩は、非水溶性薬効成分に対して1〜100重量%、特に5〜30重量%が好ましい。1〜100重量%であれば、安定したマイクロエマルションを生成でき、また風味の優れた口腔用組成物となる。
【0011】
非イオン性界面活性剤は、例えばポリオキシアルキレン付加系界面活性剤、アミンオキサイド系界面活性剤、モノまたはジエタノールアミド系界面活性剤、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、ショ糖脂肪酸エステルが好ましく、モノステアリン酸ポリオキシエチレンソルビタン(20E.O.)、ポリオキシエチレン硬化ヒマシ油(60E.O.)が特に好ましい。本発明ではこれらを1種以上用いることができる。非イオン性界面活性剤は、非水溶性薬効成分に香料を加えた疎水性成分に対して100〜250重量%、特に130〜200重量%が好ましい。100〜250重量%であれば、安定したマイクロエマルションを生成でき、また風味の優れた口腔用組成物となる。
【0012】
水はマイクロエマルションの合成に必須の成分であり、非水溶性薬効成分、香料、N−α−長鎖アシル塩基性アミノ酸アルキルエステルまたはその塩、及び非イオン性界面活性剤の合計量の5〜500重量倍、特に50〜300重量倍配合することが好ましい。
【0013】
上記4成分を任意の順番で混合することにより、高い機械的エネルギーを加えることなく、容易にメジアン径0.1μm以下、好ましくは0.09μm以下のマイクロエマルションからなる口腔用組成物を製造することができる。なお本発明の効果を害さない範囲で一般的に口腔用組成物に配合されるエタノール等の溶剤、グリセリン等の湿潤剤、メントール、メンチルラクテート等の冷感剤、カプサイシン及びその誘導体等の温感剤、ソルビトール、サッカリンナトリウム等の甘味料、p−安息香酸メチル等の保存剤、塩化亜鉛、乳酸アルミ、タンニン、サポニン、有機酸塩等の収斂剤、カルボン、アネトール、ペパーミントオイル等の香料成分等を配合できる。特にマイクロエマルションの安定性等の観点から、エタノールを配合することが好ましい。エタノールの配合量は非水溶性薬効成分に香料を加えた疎水性成分に対して100〜250重量%が好ましい。
【0014】
本発明の口腔用組成物は、洗口剤、うがい剤、水歯磨き剤等として用い得るが、歯ぐきケア洗口剤として用いることが特に好ましい。
【0015】
【実施例】
次に実施例を示して本発明をさらに詳細に説明する。
【0016】
実施例1、2及び比較例1〜6
実施例1及び2は、表1に示す配合中、水0.30重量部と水以外の成分とを混合、撹拌した後、残りの水を加え、表1に示すメジアン径と外観を有するマイクロエマルションを製造した。比較例1〜6は、表1に示す配合の全成分を混合、撹拌し、表1に示すメジアン径と外観を有するマイクロエマルションまたはマクロエマルションを製造した。
【0017】
【表1】

Figure 0003938632
【0018】
試験例1
上記で得られたマイクロエマルションまたはマクロエマルションを5℃、25℃、40℃及び50℃で30日間保存し、エマルションの安定性を目視確認した。結果を表1に示す。表1中、○は安定、×は不安定であることを示す。比較例1は40℃及び50℃で不安定であったが、それ以外はすべての温度で安定であった。
【0019】
試験例2
比較例1以外の各エマルションについて、ケラチンパウダー(平均粒径8μm、蛋白含量95重量%)へのビタミンEの吸着率を以下の方法により測定した。すなわち、各エマルション10gにケラチンパウダー0.25gを加え30秒間攪拌後、遠心分離(3000rpm 、3分間)を行った。分離したケラチンパウダーにイオン交換水10gを加え30秒間攪拌後、再び遠心分離を行い洗浄した。この洗浄操作を2回繰返した後、分離したケラチンパウダーにメタノールを加え、30秒間攪拌してビタミンEを抽出し、定量し、用いたエマルション中のビタミンE量に対する吸着量の比(%)で表した。結果を表1に示す。実施例1及び2のマイクロエマルションは、比較例6のエマルションより吸着率が高く、特に実施例1の吸着率が顕著に高かった。比較例2〜5は比較例6より吸着率が低かった。
【0020】
実施例3〜9
表2に示す配合の全成分を混合、撹拌し、表2に示すメジアン径を有するマイクロエマルションからなる口腔用組成物を製造した。これらの口腔用組成物を歯ぐきに塗布したところ、風味に優れるとともに、非水溶性薬効成分が多量かつ長時間歯ぐきに吸着した。
【0021】
【表2】
Figure 0003938632
【0022】
【発明の効果】
本発明の口腔用組成物は風味に優れ、これを用いれば、口腔内粘膜、特に歯ぐきに対する非水溶性薬効成分の吸着性が向上する。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a composition for oral cavity having an improved adsorption rate of water-insoluble medicinal ingredients to oral mucosa, particularly gums.
[0002]
[Prior art]
Oral compositions usually contain a medicinal component, and the medicinal agent acts on the affected area in the oral cavity to prevent and treat various diseases in the oral cavity. The most important function in such a composition for oral cavity is that the blended medicinal component is adsorbed to the affected area in the oral cavity and acts effectively. However, when water-insoluble medicinal ingredients such as vitamin E are blended, a large amount of a surfactant is required, so that the flavor is bad, and medicinal ingredients are discharged during rinsing, and there is hardly anything adsorbed to the mucous membrane.
[0003]
In order to solve this, for example, DL-pyrrolidone carboxylate (CAE) of N-α-coconut oil fatty acid acyl-L-arginine ethyl ester is blended with water-insoluble medicinal ingredients, ethanol and water, and the median diameter is 2 μm or less. An emulsion composition for oral cavity (Japanese Patent Laid-Open No. 4-5221) is known.
[0004]
[Problems to be solved by the invention]
However, the composition for oral cavity of Japanese Patent Application Laid-Open No. 4-5221 is somewhat excellent in the adsorptivity of the water-insoluble medicinal component to the gums, but is required to have a better adsorbability improving effect and the median. When the diameter is too small, there is also a problem that the adsorptivity to the mucous membrane is lowered. Furthermore, since CAE is used in a relatively large amount, it is not always satisfactory in terms of flavor.
[0005]
Accordingly, an object of the present invention is to provide a composition for oral cavity that further improves the adsorptivity of water-insoluble medicinal ingredients to the oral mucosa, particularly gums, and is excellent in flavor.
[0006]
[Means for Solving the Problems]
The inventors of the present invention have conventionally thought that if the particle size becomes too small, the adsorptivity of the medicinal component to the mucous membrane decreases, but a long-chain acyl basic amino acid alkyl ester or a salt thereof and a nonionic surfactant In combination with a microemulsion having a median diameter of 0.1 μm or less, the adsorptivity of the medicinal component to the oral mucosa, particularly the gums, is further improved, and the amount of the long-chain acyl basic amino acid alkyl ester or a salt thereof The present invention has been completed by finding that the flavor can be improved.
[0007]
That is, the present invention comprises a water-insoluble medicinal component 0.001-2% by weight , N-α- C 8 -C 22 fatty acid acyl-L-arginine alkyl ester or a salt thereof, a nonionic surfactant , water and ethanol . The content of the nonionic surfactant is 130 to 250% by weight based on the total amount of the fragrance added to the water-insoluble medicinal component, and the content of ethanol is the sum of the fragrance added to the water-insoluble medicinal component The composition for oral cavity which consists of 100-250 weight% with respect to quantity and consists of a microemulsion with a median diameter of 0.1 micrometer or less is provided.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
In the present invention, the water-insoluble medicinal component is not particularly limited. For example, water-insoluble vitamins (A, D, E, F, K, P, etc.) and derivatives thereof, glycyrrhetinic acid, azulene derivatives, steroids, antiplasmin agents Water-insoluble fungicides, phthalides, nicotinic acid derivatives, and organic solvent extracts of herbal medicines such as Maronier, Birch, Senkyu, Toki, Hypericum, Assembly, Hibamata, etc., and one or more of these can be used . The amount of the water-insoluble medicinal component is preferably 0.001 to 2% by weight, particularly preferably 0.01 to 1% by weight.
[0009]
The acyl group of the N-α-long chain acyl basic amino acid alkyl ester is preferably a saturated or unsaturated natural or synthetic fatty acid residue having 8 to 22 carbon atoms, particularly preferably a coconut oil fatty acid residue. For example, ornithine, lysine and arginine are preferable as the basic amino acid moiety, and arginine is particularly preferable. The basic amino acid moiety may be optically active or racemic. The alkyl ester is preferably a lower alkyl ester such as methyl ester, ethyl ester, or propyl ester, and particularly preferably ethyl ester.
[0010]
The salt of the N-α-long-chain acyl basic amino acid alkyl ester is preferably an inorganic acid salt such as hydrochloride, or an organic acid salt such as pyrrolidone carboxylate, and particularly preferably pyrrolidone carboxylate. The most preferable N-α-long chain acyl basic amino acid alkyl ester or salt thereof is CAE. The N-α-long chain acyl basic amino acid alkyl ester or a salt thereof is preferably 1 to 100% by weight, particularly 5 to 30% by weight, based on the water-insoluble medicinal component. If it is 1-100 weight%, the stable microemulsion can be produced | generated and it will become an oral composition excellent in flavor.
[0011]
Nonionic surfactants are preferably, for example, polyoxyalkylene addition surfactants, amine oxide surfactants, mono- or diethanolamide surfactants, sorbitan fatty acid esters, glycerin fatty acid esters, and sucrose fatty acid esters. Polyoxyethylene sorbitan stearate (20E.O.) and polyoxyethylene hydrogenated castor oil (60E.O.) are particularly preferred. In the present invention, one or more of these can be used. The nonionic surfactant is preferably 100 to 250% by weight, particularly 130 to 200% by weight, based on the hydrophobic component obtained by adding a fragrance to the water-insoluble medicinal component. If it is 100 to 250% by weight, a stable microemulsion can be produced, and an oral composition having an excellent flavor can be obtained.
[0012]
Water is an essential component for the synthesis of a microemulsion, and 5 to 5 of the total amount of a water-insoluble medicinal component, a fragrance, an N-α-long chain acyl basic amino acid alkyl ester or a salt thereof, and a nonionic surfactant. It is preferable to blend 500 times by weight, particularly 50 to 300 times by weight.
[0013]
By mixing the four components in any order, an oral composition comprising a microemulsion having a median diameter of 0.1 μm or less, preferably 0.09 μm or less can be easily produced without adding high mechanical energy. Can do. It should be noted that a warm feeling such as a solvent such as ethanol, a wetting agent such as glycerin, a cooling sensation agent such as menthol and menthyl lactate, capsaicin and its derivatives, etc., which are generally blended in an oral composition as long as the effects of the present invention are not impaired. , Sorbitol, sweeteners such as sodium saccharin, preservatives such as methyl p-benzoate, astringents such as zinc chloride, aluminum lactate, tannin, saponin, organic acid salts, and flavoring ingredients such as carvone, anethole, peppermint oil, etc. Can be blended. In particular, ethanol is preferably added from the viewpoint of the stability of the microemulsion. The blending amount of ethanol is preferably 100 to 250% by weight based on the hydrophobic component obtained by adding a fragrance to the water-insoluble medicinal component.
[0014]
The composition for oral cavity of the present invention can be used as a mouthwash, a mouthwash, a water toothpaste, and the like, but is particularly preferably used as a gum care mouthwash.
[0015]
【Example】
EXAMPLES Next, an Example is shown and this invention is demonstrated further in detail.
[0016]
Examples 1 and 2 and Comparative Examples 1-6
In Examples 1 and 2, in the formulation shown in Table 1, 0.30 parts by weight of water and components other than water were mixed and stirred, then the remaining water was added, and the median diameter and appearance shown in Table 1 were added. An emulsion was prepared. In Comparative Examples 1 to 6, all the components having the formulations shown in Table 1 were mixed and stirred to produce microemulsions or macroemulsions having the median diameter and appearance shown in Table 1.
[0017]
[Table 1]
Figure 0003938632
[0018]
Test example 1
The microemulsion or macroemulsion obtained above was stored at 5 ° C, 25 ° C, 40 ° C and 50 ° C for 30 days, and the stability of the emulsion was visually confirmed. The results are shown in Table 1. In Table 1, ○ indicates stable and × indicates unstable. Comparative Example 1 was unstable at 40 ° C. and 50 ° C., but otherwise stable at all temperatures.
[0019]
Test example 2
For each emulsion other than Comparative Example 1, the adsorption rate of vitamin E to keratin powder (average particle size 8 μm, protein content 95% by weight) was measured by the following method. That is, 0.25 g of keratin powder was added to 10 g of each emulsion, stirred for 30 seconds, and then centrifuged (3000 rpm, 3 minutes). 10 g of ion-exchanged water was added to the separated keratin powder, and the mixture was stirred for 30 seconds and then centrifuged again and washed. After repeating this washing operation twice, methanol is added to the separated keratin powder, vitamin E is extracted by stirring for 30 seconds, quantified, and the ratio (%) of the amount of adsorption to the amount of vitamin E in the emulsion used. expressed. The results are shown in Table 1. The microemulsions of Examples 1 and 2 had a higher adsorption rate than the emulsion of Comparative Example 6, and in particular, the adsorption rate of Example 1 was significantly higher. Comparative Examples 2-5 had a lower adsorption rate than Comparative Example 6.
[0020]
Examples 3-9
All the ingredients of the formulation shown in Table 2 were mixed and stirred to produce an oral composition comprising a microemulsion having the median diameter shown in Table 2. When these oral compositions were applied to the gums, the flavor was excellent, and a large amount of water-insoluble medicinal ingredients were adsorbed on the gums for a long time.
[0021]
[Table 2]
Figure 0003938632
[0022]
【The invention's effect】
The composition for oral cavity of this invention is excellent in flavor, and if this is used, the adsorptivity of the water-insoluble medicinal component to the oral mucosa, particularly the gums will be improved.

Claims (2)

非水溶性薬効成分0.001〜2重量%、N−α− 8 〜C 22 脂肪酸アシル−L−アルギニンアルキルエステルまたはその塩、非イオン性界面活性剤、水及びエタノールを含有し、非イオン性界面活性剤の含有量は非水溶性薬効成分に香料を加えた合計量に対して130〜250重量%、エタノールの含有量は非水溶性薬効成分に香料を加えた合計量に対して100〜250重量%であり、メジアン径0.1μm以下のマイクロエマルションからなる口腔用組成物。Water-insoluble medicinal component 0.001-2% by weight , N-α- C 8 -C 22 fatty acid acyl-L-arginine alkyl ester or salt thereof, nonionic surfactant , water and ethanol The content of the surfactant is 130 to 250% by weight with respect to the total amount of the water-insoluble medicinal component added with the fragrance , and the ethanol content is 100 with respect to the total amount of the water-insoluble medicinal component added with the fragrance. An oral composition composed of a microemulsion having a median diameter of 0.1 μm or less, which is ˜250% by weight . 非イオン性界面活性剤が、ポリオキシアルキレン付加系界面活性剤、アミンオキサイド系界面活性剤、モノまたはジエタノールアミド系界面活性剤、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル及びショ糖脂肪酸エステルからなる群より選ばれる1種以上である請求項記載の口腔用組成物。The nonionic surfactant is selected from the group consisting of polyoxyalkylene addition surfactants, amine oxide surfactants, mono- or diethanolamide surfactants, sorbitan fatty acid esters, glycerin fatty acid esters, and sucrose fatty acid esters. one or more kinds of claim 1 An oral composition according to.
JP14552698A 1998-05-27 1998-05-27 Oral composition Expired - Fee Related JP3938632B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14552698A JP3938632B2 (en) 1998-05-27 1998-05-27 Oral composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14552698A JP3938632B2 (en) 1998-05-27 1998-05-27 Oral composition

Publications (2)

Publication Number Publication Date
JPH11335253A JPH11335253A (en) 1999-12-07
JP3938632B2 true JP3938632B2 (en) 2007-06-27

Family

ID=15387268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14552698A Expired - Fee Related JP3938632B2 (en) 1998-05-27 1998-05-27 Oral composition

Country Status (1)

Country Link
JP (1) JP3938632B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6017905B2 (en) * 2012-09-24 2016-11-02 花王株式会社 Oral composition
CN106456485B (en) 2014-04-21 2019-08-09 狮王株式会社 Liquid oral composition and the method for improving its freezing restoration

Also Published As

Publication number Publication date
JPH11335253A (en) 1999-12-07

Similar Documents

Publication Publication Date Title
TWI310315B (en) Taste masking of essential oils using a hydrocolloid
JP2000281551A (en) Composition for oral cavity
RU2414210C1 (en) Medication for removal of tobacco resins and based on it composition
JP3977845B2 (en) Toothpaste composition
JPH11193208A (en) Solubilized perfume-containing composition and composition for external use formulated therewith
JP3429065B2 (en) Oral liquid composition
JP2002503257A (en) Stable herbal toothpaste
JP2014162725A (en) External composition
JP3938632B2 (en) Oral composition
JP6031902B2 (en) Two-layer separated liquid oral composition
JPS63192704A (en) Cosmetic
JP2003104858A (en) Composition for oral cavity
JP4719537B2 (en) Toothpaste composition
JP2000026257A (en) Oral composition
JP3107920B2 (en) Manufacturing method of dentifrice
JPH1112144A (en) Liquid oral composition
JPH1149654A (en) Oral composition
JP4658744B2 (en) Toothpaste composition
JP3511727B2 (en) Oral composition
JP2001064136A (en) Composition for oral cavity
JPH10279427A (en) Moisture-retaining cosmetic material composition
JP2569639B2 (en) Deodorants
JP4849980B2 (en) Toothpaste composition
JP2001039826A (en) Inorganic salt-containing oil-in-water type emulsion composition
JP3710564B2 (en) Transdermal absorption-promoting skin external preparation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040914

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20050809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050816

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061017

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061218

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070320

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070323

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110406

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120406

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130406

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130406

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140406

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees